NCT06356129: An ongoing trial by Celgene
This trial is ongoing. It must report results 3 years, 8 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06356129 |
|---|---|
| Title | A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Comparing the Efficacy and Safety of Golcadomide Plus R-CHOP Chemotherapy vs Placebo Plus R-CHOP Chemotherapy in Participants With Previously Untreated High-risk Large B-cell Lymphoma (GOLSEEK-1) |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | June 19, 2024 |
| Completion date | Aug. 14, 2028 |
| Required reporting date | Aug. 14, 2029, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |